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Abstract
A rhodopsin-based homology model of the nucleotide-activated human P2Y2 receptor, including
loops, termini, and phospholipids, was optimized with Monte Carlo Multiple Minimum. Docked
UTP formed a nucleobase π–π complex with conserved Phe3.32. Selectivity-enhancing 2′-
amino-2′-deoxy substitution interacted through π-hydrogen bonding with aromatic Phe6.51 and
Tyr3.33. A “sequential ligand composition” approach for docking the flexible dinucleotide agonist
Up4U demonstrated a shift of conserved cationic Arg3.29 from the UTP γ position to δ position of
Up4U and Up4ribose. Sysnthesized nucleotides were tested as agonists at human P2Y receptors
expressed in 1321N1 astrocytoma cells. 2′-Amino and 2-thio modifications synergized to enhance
potency and selectivity; compound 8 (8 nM EC50) was 300-fold P2Y2-selective versus P2Y4. 2′-
Amine acetylation reduced potency, and trifluoroacetylation produced intermediate potency. 5-
Amino nucleobase substitution did not enhance potency through a predicted hydrophilic
interaction, possibly because of destabilization of the receptor-favored (N)-ribose conformation.
This detailed view of P2Y2 receptor recognition suggests mutations for model validation.
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P2 nucleotide receptors are activated by a range of naturally occurring extracellular
nucleotides and consist of two families: the eight subtypes of P2Y receptors, which are G
protein–coupled receptors (GPCRs) (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and
P2Y14), and the seven subtypes of P2X ligand-gated cation channels.1–5 The P2Y2 receptor
is activated by endogenous uridine 5′-triphosphate (UTP 1), adenosine 5′-triphosphate
(ATP 2), and various dinucleotides (Chart 1). It is preferentially Gq-coupled and stimulates
phospholipase Cβ (PLCβ). The P2Y2 receptor, first cloned from mice,6 is expressed in
epithelial cells, smooth-muscle cells, endothelial cells, leukocytes, osteoblasts, and
cardiomyocytes. In the central nervous system, activation of the receptor is associated with
neuronal differentiation.7 The P2Y2 receptor appears to interact with integrins to stimulate
chemotaxis and to enhance α-secretase–dependent amyloid precursor protein processing.8,9
Activation of the P2Y2 receptor causes a pronociceptive effect.10 Agonists of the P2Y2
receptor are of interest in the development of therapeutic agents for pulmonary diseases
(e.g., cystic fibrosis), salivary gland dysfunction, and ophthalmic diseases.11,12
The SAR (structure-activity relationship) of nucleotides in activating the human P2Y2
receptor has been probed.2,3,13 UTP-γ-S 3 and the dinucleoside tetraphosphates INS365
(Up4U) 4a and INS37217 (Up4dC) 4b are potent and relatively stable agonists of the P2Y2
receptor.11,14
The first site-directed mutagenesis and molecular modeling of TMs (transmembrane helical
domains) 6 and 7 of the P2Y2 receptor were reported by Erb et al.15 Modeling methods have
subsequently undergone significant development. Furthermore, a variety of newly
synthesized potent analogues of UTP are available for docking studies. Hence, in the present
study, we carried out new molecular modeling studies to predict sites of interaction of the
ligands with the P2Y2 receptor and to provide hypotheses for the design of additional
analogues. Our recent publications1,13 provided an initial rhodopsin-based homology model,
which was refined in the present study. We also have optimized agonist selectivity for the
P2Y2 receptor by synthesizing new UTP analogues, which bear modifications at the uracil
moiety and ribose ring. Thus, this study integrates the synthesis of a highly selective agonist
with modeling studies that use a molecular dynamics (MD) simulation in a phospholipidic
and aqueous environment to refine the receptor and a Monte Carlo approach to ligand
docking.
Results and Discussion
Structure of the P2Y2 Receptor
A molecular model of the P2Y2 receptor was recently published.1 In contrast to the earlier
model constructed by Erb et al15 this model of the P2Y2 receptor is a rhodopsin-based
homology model containing not only seven TMs, but also all extracellular and intracellular
hydrophilic loops. Here we present a further refined model of the P2Y2 receptor, updated by
insertion of a segment of the carboxyl-terminal (CT) domain including the H8 helix
(Gly310–Met346) and the amino-terminal (NT) domain. The formal geometry of the model
was tested with the ProTable command of Sybyl as well as the Procheck software
(Supporting Information).16
Inclusion of the natural environment of the receptor was previously shown to significantly
improve the results of MD simulation, providing a more accurate structure of the receptor,
especially in its loop and terminal regions.17 Therefore, the model was subjected to 10 ns
MD simulation in a hydrated phospholipid bilayer.
Ivanov et al. Page 2










The MD trajectory was analyzed, and the root mean square deviations (RMSD) of the P2Y2
receptor atoms, as well as its total energy, were calculated (Supporting Information). The
analysis of the variation of the RMSD and the total energy along the trajectory suggested
that during MD simulation the receptor structure became stable after 7.5 ns. Thus, we
prolonged the simulation up to 10 ns and used the final typical structure for our docking
studies. Also, the RMS fluctuations (RMSF) of the P2Y2 receptor residues were calculated
from the MD trajectory. As shown in Figure 1, the lowest RMSF values were obtained for
amino acid residues located in TM domains, and the highest values corresponded to residues
located in the hydrophilic loops and terminal domains. The superimposition of the Cα atoms
of the TM domains of the initial structure of the P2Y2 receptor and its typical structure
calculated from the final 100 ps of the MD trajectory (Figure 2) demonstrated that the
configuration of the loops and terminal domains was most significantly changed.
Extracellular Regions—Recent MD simulation of the P2Y6 receptor revealed that EL2
moved toward TM3 and further up into the extracellular space, opening the putative
nucleotide binding cavity.18 However, in the case of the P2Y2 receptor, EL2 did not show a
significant displacement during the MD simulation. The analysis of the configuration of EL2
in the P2Y2 receptor structure obtained after MD simulation allowed us to propose several
key residues that could fix this loop near the TM domain (Table 1). In addition to the
disulfide bridge conserved among all GPCRs of the rhodopsin family and formed between
two cysteine residues located in TM3 and EL2 (C106 and C183 in the P2Y2 receptor), we
found that several charged residues located in EL2 of the P2Y2 receptor can interact with
some oppositely charged residues located around the loop (Figure 3A). In particular, three
pairs of such residues were observed: R177(EL2)-E20(NT), R180(EL2)-E29(NT), and
D185(EL2)-R265(6.55). Throughout this paper we use the GPCR residue indexing system
for TM regions, which allows comparison among receptors, as explained in detail
elsewhere.17 In addition, E190 can interact with R194; both residues are located at the
beginning of EL2. Several other bridges in the extracellular region of the P2Y2 receptor
appeared in the model. R24(NT) can interact with D97(EL1) and with D30 (NT).
Furthermore, E20(NT) interacted not only with R177(EL2), but also with R26(NT). Finally,
C25, located in the NT domain, and C278, located in EL3 formed a disulfide bridge
characteristic of all P2Y receptors.
Intracellular Regions—Three possible pairs of charged residues were found in the
intracellular region of the P2Y2 receptor: D319-R340, R334-D342, and R335-D345 (Figure
3B). All these residues are located in the CT domain. Our molecular model suggests that
ionic interactions between these residues keep the long CT domain in a more compact and
configurationally restricted form, giving the entire receptor a more densely packed structure.
The RMSF values obtained for the residues located in the H8 helix (Figure 1B) showed that
this part of the receptor remained stable during MD simulation, and H8 was found to be
helical in the typical structure of the P2Y2 receptor.
Putative Interhelical Disulfide Bridges—An analysis of the model obtained after MD
simulation allowed us to hypothesize that two pairs of cysteine residues, C132(3.51)-C217
(5.57) and C44 (1.43)-C300 (7.47), can be involved in the formation of disulfide bridges
(Figure 3B). The distances observed between Cβ atoms of these cysteines (6.2Å and 4.5Å,
respectively) are in good agreement with the distances measured experimentally for
disulfide-bonded Cys-Cys pairs.19 However, C1.43 and C3.51 are present in the P2Y2
receptor only; in other subtypes of P2Y receptors these residues are F1.43 and Y3.51 (F3.51
in the P2Y13). For this reason, these two proposed disulfide bridges could only exist in the
P2Y2 receptor. It has been shown experimentally that in rhodopsin the formation of a
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disulfide bond between residues located at the 3.51 and 5.57 positions is possible and that a
crosslink between Y3.51C and C5.57 inhibits rhodopsin activation.20
Putative Binding Modes of P2Y2 Receptor Agonists
Binding mode of UTP and its analogues—To study the putative binding modes of
P2Y2 receptor agonists, we performed molecular docking combined with Monte Carlo
Multiple Minimum (MCMM) conformational search analysis on several known nucleotide
ligands of this receptor subtype. As described in the Experimental Section, UTP 1 initially
was manually docked inside the putative binding site of the P2Y2 receptor. The published
data of site-directed mutagenesis combined with computational studies of P2Y receptors
were taken into account.1,13,18 Because the Northern (N) conformation of the ribose ring of
the ligand was proposed to be important for recognition,21 UTP and all other studied ligands
were sketched and initially docked in their (N)-conformation. In addition, the anti-
conformation of the ligand base ring was used during the modeling studies. Interestingly, in
the original rhodopsin-based model of the P2Y2 receptor,1 the side chain of one of the key
cationic residues, namely R3.29, was oriented in the opposite direction from the putative
binding pocket, but during the simulation it shifted toward the binding cavity.
After MCMM refinement of the initially obtained docking complex, the α-phosphate group
of the UTP triphosphate chain was bonded to R7.39, whereas R6.55 could interact with both
α- and γ-phosphate groups and R3.29 interacted with the γ-phosphate group of UTP
(Figure 4A). In addition, the γ-phosphate group of the ligand formed H-bonds with H184,
located in EL2 directly after the conserved cysteine residue, with the backbone nitrogen
atom of D185 and with the hydroxyl group of Y6.59. Another tyrosine residue, Y3.33, was
H-bonded to the β-phosphate group.
In the model obtained after MCMM calculations, the 2′-hydroxyl group of UTP appeared
near the conserved F6.51 (in the P2Y11 and P2Y14 receptors this position is Y6.51). This
observation suggests the possibility of OH/π H-bonding between the 2′-hydroxyl group and
the aromatic ring of F6.51. Several examples of similar interactions seen in protein
crystallographic structures were reviewed by Meyer et al.22 The hypothesis of H-bonding of
the 2′-hydroxyl group to the receptor is consistent with the experimental SAR.13 For
example, 2′-deoxy-UTP (EC50 = 1.08 μM) is 22-fold less potent than UTP (EC50 = 0.049
μM), whereas the replacement of the 2′-hydroxyl group by a 2′-methoxy group (EC50 =
14.3 μM) reduced the potency further (290-fold weaker than UTP). In the latter case, our
model showed that not only was the suggested OH/π H-bond lost, but the 2′-methyl group
also interfered sterically with the aromatic ring of F6.51.
Agonist activities of the ligands, taken together with the binding mode obtained, strongly
suggest that the hydroxyl group at the 2′-position is important as a donor but not as an
acceptor of a H-bond. The binding mode of 2′-deoxy-2′-amino UTP 6 (Table 2, EC50 =
0.062 μM), which was found to maintain potency in activation of the P2Y2 receptor,13 was
studied with MCMM calculations. The 2′-amino group (pKa = 6.2 in a related
derivative)40,41 was examined in both unprotonated and protonated, positively charged
forms. Similarly to the 2′-hydroxyl group of UTP, the 2′-amino group of 6 was found near
and oriented toward the aromatic ring of F6.51. Both protonated and unprotonated forms of
the ligands interacted with this residue. However, the protonated form of this amino group
was involved in a stronger cation/π interaction with F6.51. In addition, the protonated 2′-
NH3+ group acted as a H-bond donor to the hydroxyl of Y3.33 in our model (Figure 4B).
In the receptor-ligand complexes obtained for all studied agonists, the 3′-hydroxyl group of
the ligand appeared to be H-bonded with the α-phosphate group of the triphosphate chain.
This could be an important intramolecular interaction to stabilize the ribose ring in its (N)-
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conformation, to facilitate the interaction of the 2′-hydroxyl group with F6.51. This
assumption is in agreement with the ligand activities;13,21 both 3′-deoxy-3′-methoxy-UTP
and (S)-methanocarba ATP are essentially inactive at the P2Y2 receptor.
Taken together these findings are in good agreement with the SAR data and can explain the
experimentally observed differences in activities of UTP and its 3′- and 2′-substituted
derivatives: UTP ≈ 2′-NH2-2′-dUTP > 2′-dUTP > 2′-OCH3-2′-dUTP ≫ 3′-OCH3-3′-
dUTP.
In our model the oxygen atom at position 4 of the UTP uracil ring was H-bonded to the
hydroxyl group of Y1.39, and S7.43 accepted a H-bond from the 3-NH group of the ligand.
In contrast, the oxygen atom at position 2 was not involved in H-bonding with the receptor.
In addition, F3.32, conserved among all subtypes of P2Y receptors, was found to be
involved in π-π interaction with the uracil ring of UTP. Interestingly, in the model obtained
for the complex of the P2Y2 receptor with CTP (EC50 = 5.63 μM),13 the hydroxyl group of
S7.43 was involved in H-bonding with the nitrogen atom at the 3 position of the nucleobase
of CTP, but the NH2-group at the 4 position was unable to form a H-bond with Y1.39.
Furthermore, the nucleoside moiety of zebularine-5′-triphosphate (180-fold weaker than
UTP)13 docked to the P2Y2 receptor was significantly shifted from the initial position of
UTP outwardly toward Y1.39, although the ligand still maintained a H-bond with S7.43. In
addition, it was shown that a thiouracil ring can form H-bonded pairs with other
nucleobases, which are only slightly less stable than the pairs formed by unmodified
uracil.39 This means that 4-thio-UTP could be involved in the same interactions with Y1.39
as UTP. These data argue in favor of the hypothesis that in the case of the P2Y2 receptor,
Y1.39 plays a role in the recognition of the functional group at position 4 of the uracil
moiety. Available experimental data indicate that 3-methyl-UTP (EC50 = 1.20 μM) is 24-
fold weaker than UTP.13 With the aim of explaining the observed differences in activity, we
used MCMM calculations to establish a favored binding mode of 3-methyl-UTP, which was
compared to the binding mode of UTP. According to this model, the methyl group at
position 3 was located between the hydroxyl groups of Y1.39 and S7.43, and the side chain
of the serine residue was shifted by 1.5Å away from the ligand. Moreover, the backbone
oxygen atom of P7.40 also appeared near the 3-methyl group (Figure 4C).
The binding modes of 5-bromo-(EC50 = 0.75 μM), 5-iodo-(EC50 = 0.83 μM), and 5-methyl
UTP (EC50 = 0.48 μM) were determined (Figure 4D), indicating that a hydrophobic group
at position 5 of UTP was located unfavorably between the hydrophilic hydroxyl groups of
T182 (EL2) and Y1.39. The methyl groups of V181 (EL2) were also located approximately
4Å from the substituent at position 5. Therefore, our model suggested that the introduction
of a small hydrophilic group, such as an amino or hydroxyl group, at position 5 could
provide additional H-bonds with T182 and Y1.39 and thus favor potency. Also, we
predicted that an azido group would interact favorably within the available space between
Y40, R180, V181, T182, and P293.
Binding Mode of ATP—The question of whether UTP and ATP bind to the same site in
the P2Y2 receptor has already been considered.3 Because ATP 2 (EC50 = 0.085 μM) and
UTP 1 (EC50 = 0.049 μM) are nearly equipotent at the P2Y2 receptor, ATP was initially
docked (Figure 4E) at the P2Y2 receptor with the ribose in the (N) conformation and the
adenine ring in the anti-conformation and subsequently subjected to an MCMM
conformational search. Superimposition of the ATP-P2Y2 and the UTP-P2Y2 complexes
revealed that the phosphate chains and the ribose rings of these two ligands have identical
positions and configurations inside the receptor. The residues interacting with UTP were
also found to interact with ATP. In agreement with the binding mode obtained for UTP,
F3.32 was involved in a π–π interaction with the adenine ring of ATP. Also, Y1.39 was H-
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bonded with the N6-amino group, whereas S7.43 was H-bonded with the nitrogen atom at
position 1 of the adenine ring of ATP. In addition, Y2.53, conserved among receptors,
formed a H-bond with the nitrogen atom at position 1. On this basis, we P2Y1, 2, 4, 6 propose
that Y2.53 is likely more important for interactions of the P2Y2 receptor with ATP and its
derivatives than with UTP analogues.
Binding mode of Dinucleotide Agonists—The P2Y2 receptor can be activated not
only by uracil or adenine triphosphates but also by dinucleotide molecules.23,24 Dinucleotide
tetraphosphates, such as Up4U 4a or Up4dC 4b (Chart 1), have the optimal phosphate chain
length for activation of the P2Y2 receptor and tend to be more resistant to nucleotidase
degradation than the nucleoside triphosphates. In contrast, Up2U, containing only two
phosphate groups, is nearly inactive as an agonist, and Up6U is 98-fold weaker than Up4U at
the P2Y2 receptor.
To study the binding mode of dinucleotides within the P2Y2 receptor, we docked Up4U to
the putative binding site. Docking of molecules that are as complex as Up4U is challenging,
because of their large size and great flexibility. In particular, this process is especially
difficult in the absence of X-ray structures or even molecular models of the receptor
complexed with similar ligands. Several methods for docking of large ligands were
described previously.25 In particular, fragmental-guided docking methods decompose a
ligand into small fragments and then use favorable binding modes of these fragments to
determine the most favorable orientation of the whole ligand.
Here we introduce an alternative “sequential ligand composition” technique, which we
applied to the molecular docking of Up4U. With this technique, the structure of UTP docked
in the binding site of the P2Y2 receptor and subjected to MCMM calculations was
sequentially converted to Up4, Up4-ribose, and Up4U. The MCMM conformational search
analysis of the ligand and all receptor residues located within 5Å of the ligand was
performed at each stage of the computational conversion of UTP to Up4U to provide an
energetically favorable orientation and configuration of the ligand. In contrast to the docking
of the entire structure of the ligand (e.g. Up4U) at once, this method can avoid undesirable
changes in the configuration of the receptor binding site.
Thus, “sequential ligand composition” provided us with a putative binding mode of Up4U at
the P2Y2 receptor (Figure 4F and Supporting Information). In our model, the common
uridine triphosphate subset of the Up4U structure had almost the same binding mode as
UTP. However, three residues that interacted with the γ-phosphate group of UTP, i.e.
R3.29, D185 (EL2), and Y6.59, were found to be bonded to the δ-phosphate group of Up4U.
The uracil ring of UTP (uracilI) was involved in a π–π interaction with F3.32, and the uracil
ring of the second uridine moiety (uracilII) of Up4U formed π–π interactions with Y3.33,
which was also bonded to the β-phosphate group of the ligand. The oxygen atom at the 2
position of the uracilII ring could form H-bonds with Q4.57 and Y3.37. The oxygen atom of
the hydroxyl group of Y3.37 also appeared near the 3-NH groupII of the ligand and could be
involved in H-bonding with this group. As was observed with UTP, neither of the ribose
ring oxygen atoms was H-bonded to the receptor. However, the 3′-hydroxyl groups of both
uridineI and uridineII of Up4U were H-bonded to the α and δ phosphate groups,
respectively.
The model of receptor-docked Up4U is consistent with a tetraphosphate chain having the
optimal length for dinucleotide binding. The phosphate side chain of diuridine diphosphates
apparently is too short to allow uridineII to reach its binding pocket. In contrast, ligands with
longer phosphate chains, such as Up6U, are too large to be fully accommodated inside the
receptor. Also, as discussed by Brunschweiger and Müller2, among various linear
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dinucleotides only dinucleoside tetraphosphates have the same number of negatively
charged oxygen atoms as UTP.
Although H-bonds between the P2Y2 receptor and the ribose ring oxygen of uridineII of
Up4U are absent, both 2′- and 3′-hydroxyl groups were found to be H-bonded to the
receptor. The 2′-hydroxyl group was found to be H-bonded with the hydroxyl group of
Y5.38, and the 3′-hydroxyl group interacted with the backbone NH-group of V4.60. Also,
the hydroxyl group of Y6.59 appeared near the 3′-hydroxyl group of the ligand. These
observations suggest that Up4-ribose could be active at the P2Y2 receptor, as UDP-glucose
is active at the P2Y14 receptor. In the complex obtained for Up4U, both the hydroxyl group
of Tyr and the backbone NH-group of Val were found 5.5Å from the ligand.
Selective Recognition for Nucleoside Tri- and Diphosphates at P2Y2 and P2Y6
Receptors—Although UDP is almost inactive at the P2Y2 receptor,2 it is the cognate
agonist of the P2Y6 receptor. To explain these differences, we compared residues of the
P2Y2 receptor directly involved in ligand interactions with the corresponding residues of the
P2Y6 receptor (details are given in Supporting Information). The results obtained allow us to
propose that residues R/K6.55, Y/L6.59, and H184/Y178 of the P2Y2/P2Y6 receptors play a
critical role in UTP versus UDP recognition. This hypothesis will be tested in future
experiments with site-directed mutagenesis.
Exploration of SAR at the P2Y2 Receptor with the Aid of Modeling
To further examine determinants of P2Y2 receptor selectivity, we synthesized several
nucleotide derivatives and tested them for activation of the human P2Y2 and P2Y4 receptors
expressed in 1321N1 astrocytoma cells (Table 2). The 2′-amino modification of 6, which
maintained potency at the P2Y2 receptor,13 was combined with another P2Y2-favorable
modification of UTP, i.e. 2-thio, leading to 8. The requirement of a free amine at this
position was explored through N-acylation reactions, leading to 9 and 10. Although a 5-
methyl modification of the uracil ring of UTP was found to reduce P2Y2 receptor potency,13
we also examined whether introduction of a polar, H-bonding group such as amino at this
position would be beneficial. Thus, the 5-amino 17 and 5-azido 18 analogues were evaluated
at the receptors.
Chemical Synthesis—2′-Amino-2′-deoxy-2-thiouridine 5′-triphosphate 8 was prepared
by standard phosphorylation of the corresponding nucleoside 15. The synthesis of 2′-
amino-2′-deoxy-2-thiouridine 15 is depicted in Scheme 1. 2′-Azido-2′-deoxyuridine 12 was
obtained via opening of 2,2′-anhydrouridine with NaN3 in DMF.27 After selective
mesylation of the 5′-hydroxyl group of 12, the resulting 5′-methanesulfonate ester 13 was
converted to 2′-azido-2′-deoxy-2-O-ethyluridine (14) according to the method of
Manoharan and coworkers.28 In this reaction, 2,5′-anhydro-2′-azido-2′-deoxyuridine was
generated in situ and subsequently opened with ethoxide. Treatment of 14 with H2S in
anhydrous pyridine allowed simultaneous 2-thionation and reduction of the 2′-azido group,
resulting in 2′-amino-2′-deoxy-2-thiouridine (15). The 2-thionation was confirmed by
the 13C NMR resonance signal of C-2, which shifts to a low magnetic field (177.66 ppm)
compared to uridine (150.66 ppm).
Attempts to directly phosphorylate compound 15 by a standard method failed to yield the
desired 5′-triphosphate 8. Therefore, the 2′-amino group was protected by
trifluoroacetylation. The phosphorylation of the protected nucleoside 16 was performed as
shown in Scheme 2.29 During purification by ion exchange chromatography, partial
hydrolysis yielded a mixture of 8 and 9, which was readily separable by HPLC. The
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acetylation of the 2′-amino group of 8 to obtain 10 was performed as shown in Scheme 3.
Up4ribose 5 was prepared as shown in Scheme 4.
Pharmacological Activity—Activation of PLC by a range of concentrations of each
nucleotide derivatives was studied in 1321N1 astrocytoma cells stably expressing the human
P2Y2, P2Y4 and P2Y6 receptors (Table 2), by reported methods.13,21,30,31 Tritiated inositol
phosphates produced from a radiolabeled myo-inositol precursor were measured using a
standard ion exchange method.
An intermediate structure related to the modeling by “sequential ligand composition”, Up4-
[5′]-ribose 5, activated the P2Y2 receptor with an EC50 of 1.88 μM, i.e. 9-fold less potent
than Up4U
The 5′-triphosphate 8, which combined potency-enhancing features derived from our
previous studies, was 300-fold selective in activation of the P2Y2 receptor in comparison
with the P2Y4 receptor (Figure 5). Compound 8 and other 2′-deoxy-2′-amino analogues, 6,
9, and 10, were nearly inactive at the P2Y6 receptor. The binding mode of this potent and
selective analogue was studied with MCMM calculations, and the results were similar to
those for 6, in which the 2′-amino group in its protonated form was involved in a cation-π
interaction with F6.51 and as a H-bond donor to Y3.33 (Figure 4B). The potency of 8 was
greatly reduced upon acetylation (10) and reduced to a lesser degree upon
trifluoroacetylation (9). These observations are consistent with the binding modes obtained
for compound 10. In the model of the P2Y2 receptor complex with compound 10
(Supporting Information), the H-bond between F6.51 and the NH-group of the acetamide
moiety was not observed. Moreover, the methyl group of this moiety undesirably appeared
near the OH-group of Y3.33 and the NH2-group of R6.55. The oxygen atom of the acetyl
group was not involved in interactions with the receptor. We speculate that in the case of
compound 9, the CF3-group, which is more electronegative than CH3, provides some
favorable interactions with positively charged R6.55, improving the potency of compound
10.
The 5-position was predicted to accommodate an azido group as well as a small, polar, H-
bonding group, such as an amino group. Building on these observations, we measured the
activities of 5-amino 17 and 5-azido 18 UTP derivatives at the human P2Y2 receptor (Table
2). However, the results indicated that both structures are less active than 5-methyl-UTP 19
at this receptor.13 Similar to certain other uracil-substituted uridine 5′-triphosphates,26
compounds 17 – 19 also potently activated the human P2Y6 receptor.
Introduction of an amino or azido group at position 5 of UTP apparently influences the
conformation of the ribose ring. It was shown previously,32 through NMR analysis
combined with semiempirical calculations, that electron-donating groups at position 5 of
uracil nucleotides can destabilize the receptor-preferred (N) conformation of the ribose ring.
Conclusions
This detailed view of molecular recognition at the P2Y2 receptor suggests mutations for
further model validation. In this study we report a highly potent and selective agonist, the
2′-amino-2-thio derivative of UTP, compound 8, which should prove very useful as a
pharmacological probe for studying P2Y2 receptor action. Modeling provided an
explanation for the general stabilizing effect of the 2′-amino modification of UTP in P2Y2
receptor recognition. A “sequential ligand composition” approach was adopted for docking
flexible dinucleotide agonists such as Up4U. This modeling approach, in which ligands are
docked to the receptor, including loops and terminal regions; embedded in a phospholipid
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bilayer; and optimized with MCMM, promises to be helpful in the design of additional
potent and selective P2Y2 receptor agonists.
Experimental Section
Chemical Synthesis
All reagents were from standard commercial sources and of analytic grade. Compounds 17
and 18 were purchased from ALT, Inc. (Lexington, KY). 2,2′-Anhydrouridine (11) was
obtained from Wako Chemicals GmbH (Neuss, Germany). Precoated Merck silica gel F254
plates were used for TLC, and spots were examined under ultraviolet light at 254 nm and
further visualized by sulphuric acid-anisaldehyde spray. Column chromatography was
performed on ICN silica gel (63–200 μm, 60Å, ICN Biochemicals, Eschwege, Germany).
For compounds 11–15, NMR spectra were obtained with a Varian Mercury 300 MHz
spectrometer. Chemical shifts are given in ppm (δ) relative to the residual solvent signal, in
the case of DMSO-d6 2.54 ppm for 1H and 40.5 ppm for 13C. Structural assignment was
confirmed with COSY and DEPT experiments. All signals assigned to hydroxyl groups were
exchangeable with D2O. Exact mass measurements were performed on a quadruple/
orthogonal–acceleration time-of-flight (Q/oaTOF) tandem mass spectrometer (qToF 2,
Micromass, Manchester, UK) equipped with a standard electrospray ionization (ESI)
interface. Samples were infused in a 2-propanol/water (1:1) mixture at 3 μL/min. For
compounds 16 and 8–10, 1H NMR spectra were obtained with a Varian Gemini 300
spectrometer (Varian, Inc., Palo Alto, CA). 31P NMR spectra were recorded at room
temperature with a Varian XL 300 spectrometer (121.42 MHz); orthophosphoric acid (85%)
was used as an external standard. Purity of compounds was checked with a Hewlett–Packard
1100 HPLC equipped with a Zorbax Eclipse 5 μm XDB-C18 analytical column (250 ×4.6
mm; Agilent Technologies Inc., Palo Alto, CA). Purity was measured with two different
solvent systems. (System A: 5 mM TBAP (tetrabutylammonium dihydrogenphosphate)-
CH3CN from 80:20 to 40:60 in 20 min; flow rate 1 mL/min. System B: 10 mM TEAA
(triethylammonium acetate)-CH3CN from 80:20 to 60:40 in 20 min; flow rate 1 mL/min.
System C: 10 mM TEAA - CH3CN from 100:0 to 80:20 in 20 min; flow rate 1 mL/min.)
Purifications by HPLC were performed under the following conditions: Luna 5 μ RP-C18
(2) semipreparative column, 250 ×10.0 mm, Phenomenex, Torrance, CA; flow rate 2 mL/
min. System D: 10 mM TEAA-CH3CN from 100:0 to 90:10 in 20 min. System E: 10 mM
TEAA-CH3CN from 100:0 to 95:5 in 30 min; High-resolution mass measurements were
performed on a Micromass/Waters LCT Premier Electrospray Time of Flight mass
spectrometer coupled with a Waters HPLC system (Waters Corp., Milford, MA).
2′-Azido-2′-deoxy-5′-O-methanesulfonyluridine (13)—Methanesulfonyl chloride
(210 μL, 2.7 mmol) was added to a solution of 12 (610 mg, 2.3 mmol) in 10 mL pyridine at
−78°C. The reaction was stirred for 1 h at 0°C, quenched with aqueous saturated NaHCO3,
extracted with CH2Cl2, dried over MgSO4, filtered, and concentrated in vacuo. The residue
was purified by column chromatography (CH2Cl2:MeOH 96:4) to obtain compound 13 as a
white solid (472 mg, 61%). 1H NMR (DMSO-d6):δ 3.23 (s, 3H, CH3), 4.06 (m, 1H, H-4′),
4.25–4.48 (m, 4H, H-2′, H-3′, H-5′A, and H-5′B), 5.68 (dd, J = 7.9, 2.1 Hz, 1H, H-6), 5.82
(d, J = 5.3 Hz, 1H, 3′-OH), 6.2 (d, J = 5.6 Hz, 1H, H-1′), 7.62 (d, J = 8.2 Hz, 1H, H-5),
11.47 (s, 1H, NH); HRMS (ESI-MS) for C10H14N5O7S: [M+H]+: found, 348.0618; calcd.,
348.0613.
2′-Azido-2′-deoxy-2-O-ethyluridine (14)—Compound 13 (465 mg, 1.3 mmol) was
refluxed in absolute ethanol (60 mL) in the presence of anhydrous sodium bicarbonate (281
mg, 3.3 mmol) under a nitrogen atmosphere for 36 h. After cooling to room temperature, the
reaction was diluted with ethyl acetate and the precipitated sodium salt was removed by
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filtration. The filtrate was concentrated in vacuo and purified on a silica gel column
(CH2Cl2:MeOH 95:5) to obtain compound 14 (222 mg, 57%) as a white solid. 1H NMR
(DMSO-d6):δ 1.33 (t, J = 6.9 Hz, 3H, CH3), 3.56–3.63 (m, 1H, H-5′A), 3.67–3.74 (m, 1H,
H-5′B), 3.92 (m, 1H, H-4′), 4.12 (app t, J = 4.8 Hz, 1H, H-3′), 4.27–4.39 (m, 3H, CH2 and
H-2′), 5.23 (t, J = 4.8 Hz, 1H, 5′-OH), 5.85 (m, 2H, H-6 and 3′-OH), 6.01 (d, J = 5.4 Hz,
1H, H-1′), 7.98 (d, J = 7.8 Hz, 1H, H-5); HRMS (ESI-MS) for C11H15N5O5Na: [M+Na]+:
found, 320.0974; calcd., 320.0971.
2′-Amino-2′-deoxy-2-thiouridine (15)—In a Parr apparatus compound 14 (210 mg, 0.71
mmol) was dissolved in pyridine (40 mL), cooled to −50°C and saturated with H2S. The
mixture was heated at 50°C for 24 h, resulting in a pressure of 250 psi. After cooling to
room temperature, the remaining H2S was released, the solvent was evaporated, and the
residue was purified on a silica gel column (CH2Cl2:MeOH 90:10), yielding compound 15
(141 mg, 77%), after subsequent crystallization from MeOH. 1H NMR (DMSO-d6): δ 3.32
(dd, J = 6.1, 5.0 Hz, 1H, H-2′), 3.56–3.67 (m, 2H, H-5′A and H-5′B), 3.94 (m, 2H, H-3′
and H-4′), 5.19 (t, J = 4.7 Hz, 5′-OH), 5.41 (br s, 1H, 3′-OH), 6.01 (d, J = 8.2 Hz, 1H, H-6),
6.53 (d, J = 6.0 Hz, 1H, H-1′), 8.09 (d, J = 8.2 Hz, 1H, H-5); 13C NMR (DMSO-d6): δ 59.74
(C-2′), 61.43 (C-5′), 70.91 (C-3′), 86.50 (C-4′), 93.49 (C-1′), 107.32 (C-5), 141.66 (C-6),
160.24 (C-4), 177.66 (C-2), HRMS (ESI-MS) for C9H14N3O4S1: [M+H]+: found, 260.0692;
calcd., 260.0704.
2′-Trifluoroacetylamino-2′-deoxy-2-thiouridine (16)—N,N-Diisopropylethylamine
(0.006 mL, 0.035 mmol) and ethyl trifluoroacetate (0.004 mL, 0.035 mmol) were added
sequentially to a solution of 15 (6 mg, 0.023 mmol) in DMF (1 mL). The reaction mixture
was stirred for 13 h at room temperature. The solvent was removed in vacuo, and the residue
was purified by preparative thin-layer chromatography (CH2Cl2-MeOH, 90:10) to afford 16
(7.2 mg, 88%) as a white solid. 1H NMR (CD3OD) δ 3.84 (m, 2H, H-5′A and H-5′B), 4.14
(dd, J = 5.4, 2.7 Hz, 1H, H-4′), 4.34 (dd, J = 5.7, 3.0 Hz, 1H, H-3′), 4.58 (dd, J = 6.6, 6.3
Hz, 1H, H-2′), 6.01 (d, J = 8.1 Hz, 1H, H-6), 7.12 (d, J = 6.9 Hz, 1H, H-1′), 8.25 (d, J = 8.1
Hz, 1H, H-5); HRMS m/z found 356.0520 (M + H+)−. C11H13N3O5F3S requires 356.0528.
2′-Amino-2′-deoxy-2-thiouridine 5′-triphosphate triethylammonium salt (8) and
2′-Trifluoroacetylamino-2′-deoxy-2-thiouridine 5′-triphosphate
triethylammonium salt (9)—Phosphorous oxychloride (0.004 mL, 0.04 mmol) was
added to a solution of 16 (7.2 mg, 0.020 mmol) and Proton Sponge (4 mg, 0.033 mmol) in
trimethyl phosphate (1 mL) at 0°C. The reaction mixture was stirred for 2 h at 0°C. Then a
mixture of tributylamine (0.02 mL, 0.08 mmol) and tributylammonium pyrophosphate (1.6
moles C12H27N per mole H4PO7, 62 mg, 0.131 mmol) in DMF (0.3 mL) was added at once.
After 10 min, 0.2 M triethylammonium bicarbonate solution (2 mL) was added, and the
clear solution was stirred at room temperature for 1 h. The latter was lyophilized overnight
and the resulting residue was purified by ion-exchange column chromatography with a
Sephadex-DEAE A-25 resin with a linear gradient (0.01–0.5 M) of 0.5 M ammonium
bicarbonate as the mobile phase to get a mixture of 8 and 9 as the ammonium salts. The
mixture was purified by HPLC (System D) to obtain 8 (2.2 mg, 12 %) and 9 (1.4 mg, 7 %)
as the triethylammonium salts. Compound 8: 1H NMR (D2O) δ 1.28 (t, J = 7.5 Hz, 36H,
N(CH2CH3)3), 3.20 (q, J = 7.5 Hz, 24H, N(CH2CH3)3), 4.15 (dd, J = 6.9, 5.7 Hz, 1H, H-2′),
4.26 (m, 1H, H-5′A), 4.37 (m, 1H, H-5′B), 4.48 (m, 1H, H-4′), 4.86 (m, 1H, H-3′), 6.31 (d,
J = 8.1 Hz, 1H, H-6), 7.22 (d, J = 7.2 Hz, 1H, H-1′), 8.12 (d, J = 8.1 Hz, 1H, H-5); 31P NMR
(D2O) δ −22.64 (t, J = 20.2 Hz), −11.22 (d, J = 20.2 Hz), −9.63 (d, J = 19.6 Hz); HRMS m/z
found 497.9529 (M − H+)−. C9H15N3O13P3S requires 497.9538; purity > 98% by HPLC.
(System A: 15.2 min; System B: 6.6 min). Compound 9: 1H NMR (D2O) δ 1.28 (t, J = 7.5
Hz, 36H, N(CH2CH3)3), 3.20 (q, J = 7.5 Hz, 24H, N(CH2CH3)3), 4.32 (m, 2H, H-5′A and
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H-5′B), 4.58 (m, 1H, H-4′), 4.68 (m, 1H, H-2′), 4.80 (hidden by the water peak, 1H, H-3′),
6.26 (d, J = 8.1 Hz, 1H, H-6), 6.92 (d, J = 5.4 Hz, 1H, H-1′), 8.13 (d, J = 8.4 Hz, 1H,
H-5); 31P NMR (D2O) δ −22.28 (t, J = 19.6 Hz), −11.04 (d, J = 19.6 Hz), −8.54 (m); HRMS
m/z found 593.9364 (M − H+)−. C11H14N3O14P3F3S requires 593.9361; purity > 98% by
HPLC. (System A: 18.3 min, System B: 7.7 min).
2′-Acetylamino-2′-deoxy-2-thiouridine 5′-triphosphate triethylammonium salt
(10)—Acetic anhydride (0.07 mL, 0.74 mmol) was added to a solution of 8 (0.5 mg, 0.55
μmol) in H2O (0.5 mL) at room temperature. After the reaction mixture was stirred for 6 h,
the solvent was removed in vacuo. The residue was purified by HPLC (System D) to obtain
10 (0.3 mg, 57 %) as the triethylammonium salts. 1H NMR (D2O) δ 1.28 (t, J = 7.5 Hz, 36H,
N(CH2CH3)3), 3.20 (q, J = 7.5 Hz, 24H, N(CH2CH3)3), 4.29 (m, 2H, H-5′A and H-5′B),
4.36 (m, 1H, H-4′), 4.53 (m, 2H, H-2′ and H-3′), 6.27 (d, J = 8.1 Hz, 1H, H-6), 6.98 (d, J =
5.6 Hz, 1H, H-1′), 8.08 (d, J = 8.1 Hz, 1H, H-5); 31P NMR (D2O) δ −21.31 (t, J = 20.5 Hz),
−10.84 (d, J = 20.8 Hz), −7.62 (m); HRMS m/z found 539.9660 (M − H+)−.
C11H17N3O14P3S requires 539.9644; purity > 98% by HPLC. (System A: 17.2 min; System
B: 6.7 min).
Diuridine 5′,5′-tetraphosphate ammonium salt (4a)—Compound 4a was synthesized
by following the procedures of ref. 23. HRMS m/z found 788.9842 (M − H+)−.
C18H25N4O23P4 requires 788.9860; purity > 98% by HPLC. (System A: 20.5 min; System
C: 7.7 min).
Uridine-5′-tetraphosphate-5′-ribose triethylammonium salt (5)—Uridine 5′-
triphosphate trisodium salt (25 mg, 0.05 mmol) and D-ribose-5-monophosphate disodium
salt (59 mg, 0.19 mmol) were converted to the tributylammonium salts by treatment with the
ion-exchange resin (DOWEX 50WX2-200 (H)) and tributylamine. After removal of the
solvent, the resulting residue was dried under high-vacuum overnight. To a solution of
uridine 5′-triphosphate tributylammonium salt (0.05 mmol) in DMF (2 mL) was added N,N
′-dicyclohexylcarbodiimide (22 mg, 0.11 mmol) and the mixture stirred for 1 h at room
temperature. A solution of D-ribose-5-monophosphate tributylammonium salt (0.19 mmol)
in DMF (2 mL) was added to the reaction mixture with stirring continued at room
temperature for 48 h. After removal of the solvent, the residue was purified by ion-exchange
column chromatography with Sephadex-DEAE A-25 resin using a linear gradient (0.01–0.5
M) of 0.5 M ammonium bicarbonate as the mobile phase. Compound 5 (7.0 mg, 18 %) was
additionally purified by HPLC (System E). 1H NMR (D2O) δ 1.28 (t, J = 7.5 Hz, 36H,
N(CH2CH3)3), 3.20 (q, J = 7.5 Hz, 24H, N(CH2CH3)3), 4.11 (m, 3H, H-ribose), 4.28 (m,
4H, H-4′, H-5′, 1H-ribose), 4.42 (m, 3H, H-2′, H-3′, 1H-ribose), 5.22 (d, J = 2.4 Hz, 3/5H,
H-1′ribose), 5.41 (d, J = 3.6 Hz, 2/5H, H-1′ribose), 5.99 (d, J = 8.3 Hz, 1H, H-5), 6.02 (d, J
= 5.4 Hz, 1H, H-1′), 7.99 (d, J = 8.3 Hz, 1H, H-6); 31P NMR (D2O) δ −24.55 (m), −12.83
(m), −12.43 (m); HRMS m/z found 694.9720 (M − H+)−. C14H23N2O22P4 requires
694.9693; purity > 99% by HPLC. (System A: 18.6 min; System C: 7.1 min).
Molecular Modeling
The published molecular model of the human P2Y2 receptor1 was updated by insertion of a
part of the C-terminal (CT) domain including the H8 helix and the N-terminal (NT) domain.
The P2Y2 CT domain (residues Gly310–Met346) was modeled by homology to bovine
rhodopsin. We used the published sequence alignment,1 to superimpose the backbone atoms
of the TM domain of the P2Y2 receptor on the corresponding atoms of bovine rhodopsin
(PDB ID = 1U19)33 with Sybyl 7.1.34 The rhodopsin TM domains and its hydrophilic loops
(Ala26–Met309) as well as Gly310 of the P2Y2 receptor (last residue in the published
model) subsequently were removed from the receptor structures. The remaining rhodopsin
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NT (Met1–Glu25) and CT (residues starting from Asn310) domains were connected to
Gly22 and Ala309 of the P2Y2 receptor, respectively. The residues of the CT domain were
replaced with the corresponding residues of the P2Y2 receptor (residues Gly310–Met346)
with Sybyl 7.1.
An attempt to apply the same technique for modeling of the NT domain failed because of
overlap of the rhodopsin NT domain and the extracellular loops (ELs) of the P2Y2 receptor.
For this reason, the configuration of the P2Y2 receptor NT domain (Met1–Gly22) was
predicted with the Loopy program from the Jackal package,35 and 1000 initial
conformations were generated. The option of energy minimization of the generated
candidates was used.
The P2Y2 receptor model was minimized with Sybyl 7.1 in the Amber7 FF99 force field.
The energy minimization of side chains of the terminal domains initially was performed
with constrained positions of all other atoms of the P2Y2 receptor until an energy gradient
lower than 0.05 kcal•mol−1•Å−1 was reached. The minimization was continued without any
constraints in the terminal domains, but with constraint of the atoms of the TM helices and
hydrophilic loops. The structure was then minimized, fixing only the backbone atoms of the
TM α-helices until the energy gradient lower than 0.05 kcal•mol−1•Å−1 was reached.
Finally, an unconstrained energy minimization of the whole P2Y2 receptor model was
performed until the energy gradient was lower than 0.05 kcal•mol−1•Å−1. The formal
geometry of the model was tested with the ProTable command of Sybyl 7.1 as well as the
Procheck software.18
Molecular Dynamics Simulation of the P2Y2 Receptor
The molecular dynamics (MD) simulation of the P2Y2 receptor was performed on the NIH
Biowulf Cluster (Bethesda, MD) with CHARMM 32a2 software.36 The protocol used for
the system construction and MD simulation was described previously.18,37 The constructed
system included the P2Y2 receptor surrounded by 100 DOPC lipids, 5964 TIP3 water
molecules, and 107 Cl− and K+ ions, for a total of 37,242 atoms. The MD simulation was
performed for 10 ns under conditions of CPT (constant pressure and temperature), as
previously described.18 A hexagonal unit cell (69.3_69.3_85Å) and hexagonal periodic
boundary conditions in all directions were used.
For the first 4.5 ns of MD simulation, nuclear Overhauser effect (NOE) restraints were
applied within TM7 to the distances between each backbone carbonyl oxygen atom of
residue n and the backbone NH-group of the residue n+4. The restraints were applied to all
residues of TM7 with the exception of prolines and residues before and after prolines. MD
simulation performed without such restraints led to a disordered secondary structure of
TM7. Similar findings were described previously for the P2Y6 receptor.18 After 4.5 ns the
MD simulation was continued without any restraints, and the helical structure of the TM7
remained stable until the end of the simulation. The typical structure of the P2Y2 receptor
calculated from the last 100 ps of the MD trajectory was used as final model.
Manual Molecular Docking
The structure of UTP containing all hydrogen atoms initially was sketched with Sybyl 7.1.
The ligand geometry was optimized in the Tripos force field with Gasteiger-Hückel atomic
charges.34 Available site-directed mutagenesis data and previously published results of
molecular modeling1,13,18 were used, with the DOCK command of the Sybyl 7.1 package,34
to manually preposition UTP, with an anti-conformation of the uracil ring and an (N)-
conformation of the ribose ring, inside the putative binding site of the P2Y2 receptor. The
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tri-phosphate chain of the ligand was placed between the R3.29, R6.55, and R7.39. The
nucleobase ring was located near Y1.39, Y2.53, and S7.43.
The manual molecular docking procedure was performed in several stages. During the first
stage of the molecular docking process, only the bonds of the ligand were flexible. When the
most energetically favorable location and conformation of the ligand was found, the
molecular docking procedure was repeated with flexible bonds of the receptor. During each
iteration of the docking process, the minimization of the binding site with the ligand inside
was performed until an RMS of 0.01 kcal•mol−1•Å−1 was reached. Finally, the energy of the
entire obtained protein-ligand complex was minimized until an energy gradient lower than
0.01 kcal•mol−1•Å−1 was reached.
Conformational Analysis of UTP, ATP, and Their Derivatives
The conformational analysis of the studied mononucleotides located in the putative binding
site of the P2Y2 receptor was performed with the MCMM and the mixed torsional/low-
mode sampling methods implemented in MacroModel 9.0 software.38 MCMM calculations
initially were performed for UTP and all residues located within 5Å of the ligand, with a
shell of constrained atoms with a radius of 2Å. The following parameters were used:
MMFFs force field, water as an implicit solvent, maximum of 1000 iterations of the Polak-
Ribier Conjugate Gradient (PRCG) minimization method with a convergence threshold of
0.05 kJ•mol−1•Å−1, number of conformational search steps = 100, energy window for saving
structures = 1000 kJ•mol−1. The ligand-receptor complex obtained after MCMM
calculations was subjected to an additional 100 steps of the mixed torsional/low-mode
conformational search. The structure of UTP docked in the receptor subsequently was
transformed to other studied UTP analogues by substitution of functionalities, and MCMM
calculations were performed for each analogue, setting the number of steps to 100 and the
energy window for saving structures to 100 kJ•mol−1.
Molecular Docking of Up4U
The “subsequent ligand composition” technique was introduced to dock the dinucleotide
Up4U to the P2Y2 receptor. The UTP binding mode obtained after MCMM calculations was
used as a starting point. Initially, the δ-phosphate group was added to UTP located inside the
receptor. The resulting uridine 5′-tetraphosphate and all residues located within 5Å of the
ligand were subjected to MCMM calculations with a shell of constrained atoms within a
radius of 2Å. The following parameters were used: MMFFs force field, water as an implicit
solvent, maximum of 1000 iterations of the (PRCG) minimization method with a
convergence threshold of 0.05 kJ•mol−1•Å−1, number of conformational search steps = 100,
energy window for saving structures = 100 kJ•mol−1. A ribose moiety in its (N)-
conformation was then attached to the δ-phosphate group of the ligand. The obtained
molecule and all residues located within 5Å were also subjected to MCMM calculations
with the same parameters. The uracil ring in its anti-conformation then was attached to the
ligand. The resulting Up4U and all receptor residues located within 5Å from the ligand were
subjected to MCMM calculations with the specified parameters. Finally, Up4U and all
receptor residues located within 5Å of the ligand were subjected to an additional 100 steps
of the mixed torsional/low-mode conformational search.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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a) RMSF of the P2Y2 receptor residues calculated from the 10 ns MD trajectory. b) RMSF
of a part of C-terminal region of the P2Y2 receptor. A helical structure of H8 remained
stable during the MD simulation.
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Superimposition of the initial structure of the human P2Y2 receptor (white) and its structure
obtained after MD simulation (colored by residue position: N-terminus in red, TM1 in
orange, TM2 in ochre, TM3 – in yellow, TM4 in green, TM5 in cyan, TM6 in blue, TM7
and C-terminus in purple).
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Putative electrostatic and disulfide bridges found in the extracellular (a) and intracellular (b)
regions of the model of the P2Y2 receptor
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The binding modes of various agonists to the human P2Y2 receptor following MCMM
calculations. A) UTP 1; B) A 2′-amino-2′-deoxy analogue 8 of UTP. The 2′-amino group is
shown in its protonated form, which can be involved in cation-π interactions with F6.51 and
can form an additional H-bond with Y3.33; C) 3-Methyl-UTP.13 The 3-methyl group has an
unfavorable position between hydroxyl groups of Y1.39 and S7.43, and backbone oxygen
atom of P7.40; D) 5-Methyl-UTP 19.13 In the model obtained, the 5-methyl group of 19 is
unfavorably located between hydroxyl groups of T182 (EL2) and Y1.39. Also, it is close to
the methyl groups of V181 (EL2); E) ATP 2; F) Up4U 4a.
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Activation by compound 8 of PLC in 1321N1 astrocytoma cells expressing the human P2Y2
receptor or P2Y4 receptor.
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Preparation of the synthetic intermediate 15, a 2′-amino-2′-deoxy-2-thio nucleoside.
Reagents and conditions. (a) NaN3, DMF, 150° C, 15 h; (b) MsCl, pyridine, 0° C, 61%; (c)
NaHCO3/EtOH, reflux, 36 h, 57%; (d) H2S, pyridine, 50°C, 250 psi, 24 h, 77%.
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Synthesis of 2′-amino-2′-deoxy-2-thioUTP 8 and its N-trifluoroacetyl derivative 9.
Reagents and conditions. (a) DIEA, ethyl trifluoroacetate, DMF, room temperature, 13 h,
88%; (b) (i) POCl3, PO(OCH3)3, Proton Sponge, 0° C, 2 h, (ii) (Bu3NH+)2P2O7H2, Bu3N,
DMF, 10 min, (iii) 0.2 M triethylammonium bicarbonate solution, room temperature, 1 h,
12% (8), 7% (9).
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Synthesis of 2′-acetylamino-2′-deoxy-2-thioUTP 10. Reagents and conditions. (a) acetic
anhydride, H2O, room temperature, 6 h, 57%.
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Synthesis of Up4-5′-ribose 5. Reagents and conditions. (a) (i) DCC, DMF, room
temperature, 1h, (ii) D-ribose-5-phosphate, DMF, room temperature, 48 h, 18%.
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Structures of native nucleoside 5′-triphosphate (UTP and ATP) ligands and a dinucleotide
(UpnU) ligand of the P2Y2 receptor. EC50 values reported at the human P2Y2 receptor are
shown.13,23,24,42
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Table 1
The predicted electrostatic and disulfide bridges observed in the P2Y2 receptor model obtained after MD
simulation.
Electrostatic bridges
Negatively charged residue Positively charged residue
Glu20 NT Arg26 NT
Glu20 NT Arg177 EL2
Glu29 NT Arg180 EL2
Asp30 NT Arg24 NT
Asp97 EL1 Arg24 NT
Asp185 EL2 Arg 265 6.55
Glu190 EL2 Arg194 EL2
Asp319 CT Arg340 CT
Asp342 CT Arg334 CT
Asp345 CT Arg335 CT
Disulfide bridges
Cys25 NT Cys278 EL3
Cys106 3.25 Cys183 EL2
Putative disulfide bridges
Cys132 3.51 Cys217 5.57
Cys44 1.43 Cys300 7.47
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